Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 2

NCT07167329

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the…

Brazil100 participantsStarted 2024-01-01

Treatment: Belzutifan

RecruitingPhase 1

NCT06553339

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the…

China60 participantsStarted 2024-07-19

Treatment: Oral HS-10516

All recent trials (3 shown)

TerminatedNot Applicable

NCT00727532

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving s…

United States9 participantsStarted 2008-07

Treatment: Sorafenib